Eli Lilly and Company said on Thursday it has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy s Ltd, MSN Laboratories and Torrent Pharmaceuticals who will collaborate to accelerate and expand the availability of baricitinib in India. These three additional voluntary licensing agreements will ensure high-quality manufacturing and accessibility of baricitinib, improving local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India. Lilly received permission for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health for baricitinib to be used in combination with remdesivir for treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Read more about Dr Reddy s to manufacture baricitinib for Covid -19 treatment in India on Business Standard. Dr. Reddy s Laboratories announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture commercialisation of baricitinib in India
Story
Dr Reddy s to make, sell Eli Lilly s COVID-19 drug Baricitinib in India; 5th drugmaker to do so
Dr Reddy s has also tied up with Russian Direct Investment Fund, Russia s sovereign wealth fund that has bankrolled Sputnik V. It has also collaborated with DRDO to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which has also received approval from DCGI
BusinessToday.In | May 12, 2021 | Updated 11:31 IST
Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation
Dr Reddy s Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients who requir
May 03, 2021
Natco Pharma was trading at ₹927.60 on the BSE
The shares of Natco Pharma Ltd gained over 3 per cent on Monday, after the company announced that it has received Emergency Use approval for Baricitinib tablets for Covid-19 treatment in India.
At 10:53 am, Natco Pharma was trading at ₹927.60 on the BSE, up ₹30.95 or 3.45 per cent. II hit an intra-day high of ₹935 and an intra-day low of ₹911.40. It had opened at ₹920 as against the previous close of ₹896.65.
More
On the NSE , it was trading at ₹927.20, up 30.85 or 3.44 per cent.
The company on Monday announced that it has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.
Drug major Natco Pharma on Monday said it has received emergency use approval for Baricitinib tablets, for the treatment of COVID-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India.
CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations. Natco Pharma Ltd has received emergency use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India, the company said in a regulatory filing.